Waldencast stock falls as Raymond James reiterates Market Perform

Waldencast Acquisition Corp. (WALD) stock declined significantly after postponing its Q2 earnings release, announcing a strategic operational review, and lowering its 2025 outlook. While trading at a low 0.33x book value and maintaining 70% gross margins, the company faces challenges with debt management and profitability, leading Raymond James to maintain a Market Perform rating due to ongoing "executional challenges" despite mixed brand performance. Concurrently, WALD recently expanded its Obagi Medical brand into the growing U.S. injectable aesthetics market through the acquisition of Novaestiq Corp. and the Saypha line, a strategic move targeting multi-billion dollar market growth by 2029.

Analysis

Waldencast Acquisition Corp. (WALD) is facing significant operational and financial distress, reflected in its decision to postpone its Q2 earnings release, initiate a strategic review, and lower its 2025 outlook. This has precipitated a sharp stock decline of over 55% year-to-date, pushing its valuation to a low 0.33 times book value. While the company maintains impressive gross margins of 70%, this is contrasted by underlying issues with debt management and profitability. The mixed performance of its core brands underscores these execution challenges; Milk Makeup shows accelerating U.S. sell-out growth in the high-20s but suffers from international weakness, while Obagi's mid-teens to mid-40s growth in key channels is partially offset by distribution exits. Raymond James' cautious 'Market Perform' rating encapsulates this dichotomy, acknowledging brand potential while highlighting the persistent "executional challenges." In a concurrent strategic move, Waldencast is expanding into the high-growth U.S. injectable aesthetics market via an acquisition, targeting a combined market projected to exceed $4.2 billion by 2029. However, this long-term strategy is currently overshadowed by a severe lack of near-term visibility and operational instability.

Key Decisions for Investors

• Investors should exercise extreme caution, as the postponed earnings, lowered guidance, and strategic review are significant red flags indicating a lack of near-term visibility and potential for further negative news.
• The stock's low valuation at 0.33x book value may represent a value trap, given the company's stated challenges with debt, profitability, and operational execution.
• The outcome of the strategic review and the rescheduled earnings call are critical catalysts to monitor for any tangible plan to address the company's performance issues before considering a position.
• While the recent acquisition to enter the U.S. dermal filler market presents a long-term growth narrative, its potential is currently obscured by severe and immediate operational headwinds.